| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +6.58 M | 97.6% | $6.85 | +$45.1 M |
| Sells | 5 | -163 K | 2.4% | $14.90 | -$2.43 M |
| Net | -2 | +6.42 M | 95.2% | +$42.7 M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10%+ Owner | $179 M | +$15.1 M | +9.18% | Oct 12, 2023 |
| Samsara BioCapital GP, LLC | 10%+ Owner | $108 M | +$15 M | +16.1% | Oct 16, 2023 |
| Srinivas Akkaraju | Director | $61.1 M | +$15 M | +32.5% | Jun 27, 2024 |
| Kristina Burow | Director | $21.2 M | Jun 27, 2024 | ||
| Nagesh K. Mahanthappa | Interim CEO and President | $7.65 M | Jun 16, 2022 | ||
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER, Director | $5.55 M | -$183 K | -3.19% | Feb 16, 2024 |
| Yung H. Chyung | Chief Medical Officer | $4.12 M | Feb 14, 2022 | ||
| David Hallal | Director | $2.73 M | Jun 27, 2024 | ||
| Gregory John Carven | Chief Scientific Officer | $2.04 M | Jun 16, 2022 | ||
| Junlin Ho | General Counsel | $1.83 M | -$164 K | -8.2% | Jun 17, 2024 |
| Edward H. Myles | Coo & Cfo | $1.81 M | -$1.37 M | -43.2% | Jun 17, 2024 |
| Caryn Parlavecchio | Chro | $1.38 M | -$152 K | -9.95% | Jun 17, 2024 |
| Mo Qatanani | Chief Scientific Officer | $1.3 M | -$553 K | -29.8% | Jun 17, 2024 |
| Jing L. Marantz | Chief Medical Officer | $1.16 M | Feb 12, 2024 | ||
| Tracey Sacco | Chief Commercial Officer | $785 K | Feb 12, 2024 | ||
| Amir Nashat | Director | $608 K | May 9, 2024 | ||
| Michael Gilman | Director | $458 K | Jun 27, 2024 | ||
| Jeffrey S. Flier | Director | $402 K | Jun 27, 2024 | ||
| Katie Peng | Director | $281 K | Jun 27, 2024 | ||
| Akshay Vaishnaw | Director | $206 K | Jun 27, 2024 | ||
| Joshua Reed | Director | $121 K | Jun 27, 2024 | ||
| Richard Brudnick | Director | $121 K | Jun 27, 2024 |
| Insider | Class | Transaction | % | Value $ | Price $ | Shares | Shares Owned | Date | Ownership |
|---|